We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance for Detection of Colon Cancer

By Labmedica staff writers
Posted on 01 Aug 2002
A long-term strategic partnership has been announced to commercialize a DNA test for the early detection of colorectal cancer in the average-risk population. More...


Under their agreement, Laboratory Corporation of America Holdings (Burlington, NC, USA) will pay the developer of the test, Exact Sciences Corp. (Maynard, MA, USA), royalty fees and up to US$75 million in various payments for a five-year exclusive license, followed by a nonexclusive license for the life of the patents. Exact Sciences says there is no other DNA test currently available for the early detection of colorectal cancer in an average-risk population.

Called PreGen-Plus, the test works by isolating human DNA, shed in the colon every day and carried out of the body in stool, and by analyzing that DNA for mutations associated with colorectal cancer. PreGen-Plus is noninvasive and requires no dietary modification or bowel preparation. The process involves collecting a single stool sample and shipping the sample in a supplied container to a laboratory for analysis.

"We believe PreGen-Plus could be the most important molecular test identified to date for the millions of Americans who are candidates for colorectal cancer screening annually,” said Thomas P. MacMahon, chairman and CEO of LabCorp.




Related Links:
LabCorp
Exact Sciences

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.